Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis
{{output}}
RAS is the most frequently mutated oncogene in human cancer with nearly ~20% of cancer patients possessing mutations in one of three RAS genes (K, N or HRAS). However, KRAS is mutated in nearly 90% of pancreatic ductal carcinomas (PDAC). Although pharmacologic... ...
